Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Eisenmenger Syndrome (MAESTRO-OL)
NCT01739400Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of macitentan in Eisenmenger syndrome, sponsored by Actelion Pharmaceuticals Ltd. Started Sep 2013; status: terminated.
02
Drugs
macitentan
03
Conditions
Eisenmenger syndrome
Beyond the preview
Go deeper on NCT01739400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739400.